Skip to main content

Advertisement

SpringerLink
Log in

MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The expression of metastasis-associated in colon cancer-1 (MACC1) in non-small cell lung cancer (NSCLC) and its association with pathological characteristics and prognosis for NSCLC patients were investigated retrospectively. The expression of MACC1 was evaluated through immunohistochemical staining of tissue microarrays from 180 samples of resected lung cancer tissues and adjacent normal lung tissues. MACC1 protein and mRNA expression were also examined from lung cancer cell lines with different metastatic potentials, 28 pairs of samples of resected fresh non-small cell lung cancer tissues, and adjacent normal lung tissues. Immunohistochemical staining of tissue microarrays showed that MACC1 was located in the cytoplasm. In addition, the expression of MACC1 protein in NSCLC was significantly higher compared to adjacent normal tissues (P < 0.001). The expression of MACC1 was positively associated with differentiation grade (P = 0.020), postoperative pathological TNM stage (P = 0.033), and lymph node metastasis (P = 0.028). Disease-free survival (DFS) and overall survival (OS) for the high MACC1 expression group were lower than the low expression group; univariate and multivariate regression analyses showed that MACC1 was an independent prognostic indicator for DFS (HR 3.124, P = 0.01) and OS (HR 2.905, P = 0.01) in NSCLC patients. The expression of MACC1 protein and mRNA was also upregulated in highly metastatic human lung cancer. In conclusion, the overexpression of MACC1 protein and mRNA may represent a potentially useful biomarker for the prognosis of NSCLC patients and might be involved in progression of NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Alberg AJ, Ford JG, Samet JM, American College of Chest P. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines, 2nd edition. Chest. 2007;132(3 Suppl):29S–55S. doi:10.1378/chest.07-1347.

    Article  CAS  PubMed  Google Scholar 

  3. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15(1):59–67. doi:10.1038/nm.1889.

    Article  CAS  PubMed  Google Scholar 

  4. Kokoszynska K, Krynski J, Rychlewski L, Wyrwicz LS. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol. 2009;56(2):317–23.

    CAS  PubMed  Google Scholar 

  5. Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, et al. Overexpression of MACC1 and Its significance in human Breast Cancer Progression. Cell Biosci. 2013;3(1):16. doi:10.1186/2045-3701-3-16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Zhang RT, Shi HR, Huang HL, Chen ZM, Liu HN, Yuan ZF. Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance. J South Med Univ. 2011;31(9):1551–5.

    CAS  Google Scholar 

  7. Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. doi:10.1186/1479-5876-9-166.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z, et al. MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS ONE. 2013;8(5):e64235. doi:10.1371/journal.pone.0064235.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Meng F, Li H, Shi H, Yang Q, Zhang F, Yang Y, et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling pathway. PLoS ONE. 2013;8(4):e60821. doi:10.1371/journal.pone.0060821.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Wang G, Kang MX, Lu WJ, Chen Y, Zhang B, Wu YL. MACC1: a potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncol Lett. 2012;4(4):783–91. doi:10.3892/ol.2012.784.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 2012;32(4):1527–31.

    CAS  PubMed  Google Scholar 

  12. Hu X, Fu X, Wen S, Zou X, Liu Y. Prognostic value of MACC1 and c-met expressions in non-small cell lung cancer. Chin J Lung Cancer. 2012;15(7):399–403. doi:10.3779/j.issn.1009-3419.2012.07.02.

    Google Scholar 

  13. Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31(4):1141–5.

    PubMed  Google Scholar 

  14. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. 2011;141(4):895–8. doi:10.1016/j.jtcvs.2010.09.044.

    Article  CAS  PubMed  Google Scholar 

  15. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S. doi:10.1378/chest.12-2359.

    Article  CAS  PubMed  Google Scholar 

  16. Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, Zhu YB, et al. Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Cancer. 2011;23(2):153–9. doi:10.1007/s11670-011-0153-9.

    CAS  Google Scholar 

  17. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med. 2009;1(4):36. doi:10.1186/gm36.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 2009;41(12):2356–9. doi:10.1016/j.biocel.2009.08.001.

    Article  CAS  PubMed  Google Scholar 

  19. Stein U, Dahlmann M, Walther W. MACC1—more than metastasis? Facts and predictions about a novel gene. J Mol Med. 2010;88(1):11–8. doi:10.1007/s00109-009-0537-1.

    Article  CAS  PubMed  Google Scholar 

  20. Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg. 2013;257(6):1089–95. doi:10.1097/SLA.0b013e31828f96bc.

    Article  PubMed  Google Scholar 

  21. Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, et al. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS ONE. 2012;7(11):e49249. doi:10.1371/journal.pone.0049249.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Hongtai Ma and Lili Jia from Nanjing Medical University for technical assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, 210029, People’s Republic of China

    Zhiqiang Wang, Zhi Li, Yonggong Wang, Yang Xia, Liang Chen, Quan Zhu & Yijiang Chen

  2. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People’s Republic of China

    Chen Wu

Authors
  1. Zhiqiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yonggong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Quan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yijiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yijiang Chen.

Additional information

Zhiqiang Wang and Zhi Li have contributed equally to this work and should be regarded as joint first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Z., Li, Z., Wu, C. et al. MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer. Med Oncol 31, 790 (2014). https://doi.org/10.1007/s12032-013-0790-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0790-6

Keywords

Search

Navigation